Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1996; 27:536-542
© 1996 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kereiakes, D.
Right arrow Articles by Sax, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kereiakes, D.
Right arrow Articles by Sax, F.

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty

DJ Kereiakes, NS Kleiman, J Ambrose, M Cohen, S Rodriguez, T Palabrica, HC Herrmann, JM Sutton, WD Weaver, DB McKee, V Fitzpatrick, and FL Sax

Christ Hospital Cardiovascular Research Center, Cincinnati, Ohio 45219, USA.

OBJECTIVES: The objectives of this double-blind, placebo-controlled, randomized dose-ranging study were 1) to examine the safety and tolerability of tirofiban (MK-383), a new nonpeptide platelet IIb/IIIa receptor antagonist, on a background of intravenous heparin and aspirin therapy; 2) to study the pharmacodynamics and pharmacokinetics of tirofiban; and 3) to evaluate the incidence of adverse cardiac outcomes (urgent repeat revascularization, myocardial infarction and death) with tirofiban versus placebo in a high risk subset of patients undergoing coronary angioplasty. BACKGROUND: Abrupt vessel closure complicates 4% to 8% of angioplasty procedures. Recent data have suggested that agents that antagonize the platelet glycoprotein IIb/IIIa receptor may reduce the incidence of adverse ischemic outcomes after coronary angioplasty. METHODS: Seventy-three patients received tirofiban in three sequential dose panels and 20 patients received placebo. Patients within each panel were randomized to receive either tirofiban or placebo in a 3:1 randomization design. Bolus doses of 5, 10 and 10 microg/kg and continuous infusion (16 to 24 h) doses of 0.05, 0.10 and 0.15 microg/kg per min were administered in panels I, II and III, respectively. Patients received concomitant heparin and aspirin for the angioplasty procedure. Data on patients receiving placebo (heparin and aspirin only) were pooled across panels for comparisons. The pharmacodynamic effect of tirofiban on ex vivo platelet aggregation to 5 micromol/liter adenosine diphosphate (ADP) and bleeding times were measured. Clinical outcomes were assessed in all patients, but the power to detect clinically meaningful differences (a one-third reduction in clinical events) between groups was limited (5%). RESULTS: Tirofiban was associated with a dose-dependent inhibition of ex vivo ADP-mediated platelet aggregation that was sustained during intravenous infusion and resolved rapidly after drug cessation. Adverse bleeding events, largely related to vascular access site hemorrhage, were slightly increased at the highest dose. Adverse clinical outcomes were infrequent in all patients and were not different among the small number of patients within each group. CONCLUSIONS: This study establishes a rational and generally well tolerated dosing regimen for administration of tirofiban as adjunctive therapy in high risk angioplasty patients. The impact of tirofiban on adverse clinical outcomes after angioplasty awaits definition by a larger clinical trial.


This article has been cited by other articles:


Home page
Eur Heart JHome page
M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi, A. W.J. van 't Hof, G. Campo, C. Hamm, J. ten Berg, L. Bolognese, F. Saia, G. B. Danzi, et al.
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials
Eur. Heart J., September 14, 2009; (2009) ehp376v1.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Patrono, C. Baigent, J. Hirsh, and G. Roth
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 199S - 233S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 234S - 264S.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. Karvouni, D. G. Katritsis, and J. P. A. Ioannidis
Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions
J. Am. Coll. Cardiol., January 1, 2003; 41(1): 26 - 32.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. B. Batchelor, T. R. Tolleson, Y. Huang, R. L. Larsen, R. M. Mantell, P. Dillard, M. Davidian, D. Zhang, W. J. Cantor, M. H. Sketch Jr, et al.
Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial
Circulation, September 17, 2002; 106(12): 1470 - 1476.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. L. Frelinger III, M. I. Furman, L. A. Krueger, M. R. Barnard, and A. D. Michelson
Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation
Circulation, September 18, 2001; 104(12): 1374 - 1379.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. J. Fintel
From bench to bedside: GP IIb-IIIa inhibitors
Neurology, September 1, 2001; 57(90002): S12 - 19.
[Abstract] [Full Text]


Home page
NEJMHome page
E. J. Topol, D. J. Moliterno, H. C. Herrmann, E. R. Powers, C. L. Grines, D. J. Cohen, E. A. Cohen, M. Bertrand, F.-J. Neumann, G. W. Stone, et al.
Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization
N. Engl. J. Med., June 21, 2001; 344(25): 1888 - 1894.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. P. Abulencia, N. Tien, O. J. T. McCarty, D. Plymire, S. A. Mousa, and K. Konstantopoulos
Comparative Antiplatelet Efficacy of a Novel, Nonpeptide GPIIb/IIIa Antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis
Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 149 - 156.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth
Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects
Chest, January 1, 2001; 119 (2009): 39S - 63S.
[Full Text] [PDF]


Home page
Eur Heart JHome page
R Choussat, A Black, I Bossi, J Fajadet, and J Marco
Vascular complications and clinical outcome after coronary angioplasty with platelet IIb/IIIa receptor blockade. Comparison of transradial vs transfemoral arterial access
Eur. Heart J., April 2, 2000; 21(8): 662 - 667.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
A. M. Lincoff, R. M. Califf, and E. J. Topol
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1103 - 1115.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Verstraete
Synthetic Inhibitors of Platelet Glycoprotein IIb/IIIa in Clinical Development
Circulation, February 15, 2000; 101 (6): e76 - e80.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
A. Brodison, R. Katira, R. S More, and A. Chauhan
Current practice: Antiplatelet use in interventional cardiology
Postgrad. Med. J., February 1, 2000; 76(892): 70 - 79.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
D. J Schneider, D. J Taatjes, and B. E Sobel
Paradoxical inhibition of fibrinogen binding and potentiation of {alpha}-granule release by specific types of inhibitors of glycoprotein IIb-IIIa
Cardiovasc Res, January 14, 2000; 45(2): 437 - 446.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. B. Bussel, T. J. Kunicki, and A. D. Michelson
Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease
Hematology, January 1, 2000; 2000(1): 222 - 240.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. M. Scarborough, N. S. Kleiman, and D. R. Phillips
Platelet Glycoprotein IIb/IIIa Antagonists : What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use?
Circulation, July 27, 1999; 100(4): 437 - 444.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. F. Kong, R. M. Califf, D. P. Miller, D. J. Moliterno, H. D. White, R. A. Harrington, J. E. Tcheng, A. M. Lincoff, V. Hasselblad, and E. J. Topol
Clinical Outcomes of Therapeutic Agents That Block the Platelet Glycoprotein IIb/IIIa Integrin in Ischemic Heart Disease
Circulation, December 22, 1998; 98(25): 2829 - 2835.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R.F. Storey, R.G. Wilcox, and S. Heptinstall
Differential Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Microaggregate and Macroaggregate Formation and Effect of Anticoagulant on Antagonist Potency : Implications for Assay Methodology and Comparison of Different Antagonists
Circulation, October 20, 1998; 98(16): 1616 - 1621.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Mann, G. Cubeddu, J. Bowen, J. E. Schneider, M. Arrowood, W. N. Newman, M. J. Zellinger, and G. C. Rose
Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites
J. Am. Coll. Cardiol., September 1, 1998; 32(3): 572 - 576.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. M. Gibson, M. Goel, D. J. Cohen, R. N. Piana, L. I. Deckelbaum, K. E. Harris, S. B. King III, and for the RESTORE Investigators
Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial
J. Am. Coll. Cardiol., July 1, 1998; 32(1): 28 - 34.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. A. Bednar, S. L. Gaul, T. G. Hamill, M. S. Egbertson, J. A. Shafer, G. D. Hartman, R. J. Gould, and B. Bednar
Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets
J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1317 - 1326.
[Abstract] [Full Text]


Home page
NEJMHome page
J. H. Chesebro and J. J. Badimon
Platelet Glycoprotein IIb/IIIa Receptor Blockade in Unstable Coronary Disease
N. Engl. J. Med., May 21, 1998; 338(21): 1538 - 1541.
[Full Text]


Home page
CirculationHome page
T. R. Investigators
Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty
Circulation, September 2, 1997; 96(5): 1445 - 1453.
[Abstract] [Full Text]


Home page
CirculationHome page
D. R. Phillips, W. Teng, A. Arfsten, L. Nannizzi-Alaimo, M. M. White, C. Longhurst, S. J. Shattil, A. Randolph, J. A. Jakubowski, L. K. Jennings, et al.
Effect of Ca2+ on GP IIb-IIIa Interactions With Integrilin : Enhanced GP IIb-IIIa Binding and Inhibition of Platelet Aggregation by Reductions in the Concentration of Ionized Calcium in Plasma Anticoagulated With Citrate
Circulation, September 2, 1997; 96(5): 1488 - 1494.
[Abstract] [Full Text]


Home page
RadiologyHome page
U. Junghans, R. J. Seitz, H. J. Wittsack, A. Aulich, and M. Siebler
Treatment of Acute Basilar Artery Thrombosis with a Combination of Systemic Alteplase and Tirofiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Inhibitor: Report of Four Cases
Radiology, December 1, 2001; 221(3): 795 - 801.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement